Nektar Continues To Refocus With Sale Of Pulmonary Business To Novartis

CEO Howard Robin says firm now will focus fully on PEGylation and conjugate chemistry-based drug development.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet